Trial reportThe American journal of psychiatry2021
Moderation of Prazosin's Efficacy by Alcohol Withdrawal Symptoms.
Trial report in The American journal of psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04793685 (Prazosin Treatment for Alcohol Use Disorder With Alcohol Withdrawal Symptoms), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prazosin Treatment for Alcohol Use Disorder With Alcohol Withdrawal Symptoms
Who cites it
27 citing papers in PubMed, 53 citations in OpenAlex.
- Alcohol withdrawal symptoms predict corticostriatal dysfunction that is reversed by prazosin treatment in alcohol use disorder.Addiction biology · 2022Trial
- Prazosin in the Pharmacologic Management of Alcohol Use Disorder.Biological psychiatry global open science · 2026Article
- Prazosin-Related Reductions in Daily Craving Mediate Treatment-Related Daily Alcohol Use Outcomes in Alcohol Use Disorder.Biological psychiatry global open science · 2026Article
- A Feasibility Study of the Repurposing of Prazosin to Improve Treatment Outcomes in Men Receiving Radiotherapy for Prostate Cancer (MiniRaP-00).The Prostate · 2026Article
- Spironolactone and clinical outcomes in patients with alcohol use disorder and comorbid hypertension: a target trial emulation study.Psychopharmacology · 2026Article
- Noradrenaline Modulates Central Amygdala GABA Transmission and Alcohol Drinking in Female Rats.Biological psychiatry · 2026Article
- Early alcohol abstinence symptoms and the role of cumulative adversity.Alcohol, clinical & experimental research · 2025Article
- α1 Adrenergic Receptors Mediate Panic-like Defensive Behavior in Alcohol-Drinking but Not Alcohol-Naïve Rats.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Laboratory and Real-World Experimental Approaches to Understanding Alcohol Relapse.Current topics in behavioral neurosciences · 2025Review
- Stress and substance use disorders: risk, relapse, and treatment outcomes.The Journal of clinical investigation · 2024Review
- Sex- and estrous-related response patterns for alcohol depend critically on the level of compulsion-like challenge.Progress in neuro-psychopharmacology & biological psychiatry · 2024Article
- Greater inhibition of female rat binge alcohol intake by adrenergic receptor blockers using a novel Two-Shot rat binge drinking model.Scientific reports · 2024Article
- Greater inhibition of female rat binge alcohol intake by adrenergic receptor blockers using a novel Two-Shot rat binge drinking model.Research square · 2024Article
- Effects of prazosin treatment on liver enzymes are moderated by alcohol withdrawal symptoms in individuals with alcohol use disorder.Alcohol, clinical & experimental research · 2024Article
- The role of beta- and alpha-adrenergic receptors on alcohol drinking.Neuropharmacology · 2023Article
- Tauopathy and alcohol consumption interact to alter locus coeruleus excitatory transmission and excitability in male and female mice.Alcohol (Fayetteville, N.Y.) · 2023Article
- Utilizing precision medicine to treat alcohol use disorder: A commentary on the α1 receptor antagonist.Alcohol, clinical & experimental research · 2023Article
- Animal models of compulsion alcohol drinking: Why we love quinine-resistant intake and what we learned from it.Frontiers in psychiatry · 2023Review
- Excessive alcohol consumption after exposure to two types of chronic social stress: intermittent episodes vs. continuous exposure in C57BL/6J mice with a history of drinking.Psychopharmacology · 2022Article
- The Amygdala Noradrenergic System Is Compromised With Alcohol Use Disorder.Biological psychiatry · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
objectiveAlcohol use disorder (AUD) is a leading cause of global disease burden. Chronic, heavy use increases the likelihood of alcohol withdrawal symptoms and associated secondary outcomes of alcohol craving and mood, anxiety, and sleep disturbances, which are predictive of poor treatment outcomes. The authors examined whether alcohol withdrawal symptoms moderate the efficacy of prazosin in reducing alcohol intake and associated secondary outcomes.
methodsA 12-week, double-blind, randomized, controlled proof-of-concept trial of prazosin (16 mg/day, with a 2-week titration) was conducted in community-recruited adults with current alcohol dependence (N=100) with varying levels of alcohol withdrawal symptoms assessed at treatment entry. Primary outcomes were daily self-reported drinking days and heavy drinking days, and secondary outcomes were average drinks/day and mood, anxiety, craving, and sleep quality ratings.
resultsModified intent-to-treat analyses indicated a significant interaction of alcohol withdrawal symptom score by treatment by full-dose treatment period (weeks 3-12) for drinking days, heavy drinking days, and average drinks/day. By week 12, participants with high alcohol withdrawal symptoms on prazosin reported 7.07% heavy drinking days and 27.46% drinking days, while those on placebo had 35.58% heavy drinking days and 58.47% drinking days (heavy drinking days: odds ratio=0.14, 95% CI=0.058, 0.333; drinking days: odds ratio=0.265, 95% CI=0.146, 0.481). No such benefit of prazosin was observed in those reporting low or no alcohol withdrawal symptoms. Individuals with high alcohol withdrawal symptoms on prazosin compared with placebo also showed significantly improved anxiety, depression, and alcohol craving over the course of the trial.
conclusionsThe findings indicate that alcohol withdrawal symptoms are a significant moderator of prazosin treatment response for alcohol use outcomes and for associated symptoms of alcohol craving, anxiety, and mood symptoms. These data support further evaluation of alcohol withdrawal symptoms as a prognostic indicator of prazosin's efficacy in the treatment of AUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.